- Home
- BKYI vs QLGN Comparison
BKYI vs QLGN Comparison
Compare BKYI & QLGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BKYI
- QLGN
- Stock Information
- Founded
- BKYI 1993
- QLGN 1996
- Country
- BKYI United States
- QLGN United States
- Employees
- BKYI N/A
- QLGN 4
- Industry
- BKYI Computer Software: Prepackaged Software
- QLGN Biotechnology: Pharmaceutical Preparations
- Sector
- BKYI Technology
- QLGN Health Care
- Exchange
- BKYI Nasdaq
- QLGN Nasdaq
- Market Cap
- BKYI 3.2M
- QLGN 2.7M
- IPO Year
- BKYI 1997
- QLGN N/A
- Fundamental
- Price
- BKYI $0.94
- QLGN $3.60
- Analyst Decision
- BKYI
- QLGN
- Analyst Count
- BKYI 0
- QLGN 0
- Target Price
- BKYI N/A
- QLGN N/A
- AVG Volume (30 Days)
- BKYI 6.3M
- QLGN 226.0K
- Earning Date
- BKYI 11-14-2024
- QLGN 11-29-2024
- Dividend Yield
- BKYI N/A
- QLGN N/A
- EPS Growth
- BKYI N/A
- QLGN N/A
- EPS
- BKYI N/A
- QLGN N/A
- Revenue
- BKYI $7,292,394.00
- QLGN N/A
- Revenue This Year
- BKYI N/A
- QLGN N/A
- Revenue Next Year
- BKYI $24.64
- QLGN N/A
- P/E Ratio
- BKYI N/A
- QLGN N/A
- Revenue Growth
- BKYI N/A
- QLGN N/A
- 52 Week Low
- BKYI $0.52
- QLGN $3.55
- 52 Week High
- BKYI $4.50
- QLGN $39.15
- Technical
- Relative Strength Index (RSI)
- BKYI 45.22
- QLGN 25.42
- Support Level
- BKYI $1.13
- QLGN $3.71
- Resistance Level
- BKYI $1.31
- QLGN $4.56
- Average True Range (ATR)
- BKYI 0.17
- QLGN 0.65
- MACD
- BKYI -0.01
- QLGN -0.06
- Stochastic Oscillator
- BKYI 1.93
- QLGN 2.08
About BKYI BIO-key International Inc.
BIO-key International Inc is a fingerprint biometric technology company. It develops and markets fingerprint biometric identification and identity verification technologies, as well as related identity management and credentialing hardware and software solutions. Its product portfolio comprises SideSwipe, SidePass, EcoID, WEB-key, and others. The company generates its revenue in the form of Services, License fees, and others.
About QLGN Qualigen Therapeutics Inc.
Qualigen Therapeutics Inc is a early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. The company's business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program. The company's lead program, QN-302, is an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor with strong binding affinity to G4s prevalent in cancer cells.